Background: Growing evidence points to the role of vitamin D in the pathobiology and treatment of depression. However, the evidence is inconsistent in many aspects. The objectives of this narrative review were to evaluate the state of the evidence, synthesize the knowledge gaps, and formulate recommendations for more enhanced research in this growing area. Methods: Electronic searches of MEDLINE via PubMed, Cochrane Library, and Google Scholar databases were carried out from inception till February 2019 to identify relevant English language peer-reviewed articles. Abstracts generated were systematically screened for eligibility. Included articles were grouped under three broad themes: The association between vitamin D and depression, its biological underpinnings, and trials evaluating the efficacy of vitamin D supplementation in depression. Relevant data were extracted as per a structured proforma. Results: A total of 61 articles were included in the present review. Overall findings were that there is a relationship between vitamin D and depression, though the directionality of this association remains unclear. The association appears to be driven by the homeostatic, trophic, and immunomodulatory effects of vitamin D. Evidence from supplementation trials suggest a more robust therapeutic effect on subjects with major depression and concurrent vitamin D deficiency. Conclusion: Serum vitamin D levels inversely correlate with clinical depression, but the evidence is not strong enough to recommend universal supplementation in depression. Enriching depression treatment trials with subjects having concurrent vitamin D deficiency appears to be a potential step forward in identifying subgroups who may maximally benefit from this approach.
Depression is a common and disabling mental illness, prevalent worldwide across all ages, genders, and races. In 2015, 4.4 per cent of the world's population was suffering from depression. [1] The condition is associated with increased morbidity and mortality, owing to increased risk for stroke, cardiovascular events, and suicide as well as lifestyle-related disorders such as diabetes and hypertension. [2] [3] [4] It also has significant economic and social consequences, such as decreased productivity and increased health care utilization costs. [5, 6] Compounding the issue further, depression is associated with a high burden of nonresponse to conventional treatment options. [7, 8] Given the above scenario, clinicians and researchers are constantly looking to expand the therapeutic options to tackle depression. The last quarter of a centur y has seen research attention being increasingly centred on inflammation as a possible pathophysiological mechanism in depression. Several trials of anti-inflammatory agents have shown promise, but the evidence, so far, is not strong enough to guide clinical recommendations. [9, 10] Parallel to these developments, the role of vitamin D in depression has also received increasing research focus. Currently, there are at least three lines of evidence to support this association: first, an increased region-specific expression of vitamin D receptors (VDRs) in brain areas (such as prefrontal and cingulate cortices) known to play a key role in mood regulation; [11] second, the modulatory role proposed for vitamin D in the association between depression and inflammation (through a possible immune-modulatory mechanism) [12, 13] ; last, the emerging insights about the neuroprotective properties of vitamin D (by virtue of its anti-inflammatory effects). [14, 15] Against this background, we carried out the present narrative review to summarize the literature and clarify the evidence in three areas: association between vitamin D and depression, its underlying biological links, and therapeutic effects of vitamin D on depression. Accordingly, we had our objectives: -1) to describe the evidence for association between vitamin D and depression and outline the underlying biological mechanisms, 2) to synthesize the evidence base for effect of vitamin D supplementation in depression, and 3) to highlight the knowledge gaps in these areas and formulate recommendations that seem most relevant for future research.
METHODS

Search strategy
We carried out an electronic search of MEDLINE through PubMed, Cochrane Library and Google Scholar databases (all up to February 2019) for articles on vitamin D and depression. For PubMed search, the following MeSH or free text terms were used: 'vitamin D', 'vitamin d', '25-hydroxyvitamin d 2', ' 25 Search terms were adapted to suit the search needs of other databases as appropriate. Additionally, hand searches of the reference lists of the generated articles were done in order to ensure a comprehensive search. The searches were done by three independent reviewers, all of whom were qualified psychiatrists.
Study selection and data extraction
The initial search yielded 879 hits. We included only English language articles published in peer-reviewed journals. Editorials and commentaries were not included in the main review but only to support some recommendations, we make at the end. We also included systematic reviews and meta-analyses addressing focused research questions related to the focus areas, and the original articles included in these reviews were not examined separately. Based on these criteria and after eliminating duplicates, 148 articles were identified for potential inclusion, and after their full texts were examined, 61 papers were included in the present review after elimination of articles other than original research papers or those not relevant to the focus areas of the present review. All the three authors participated in study selection and reached a consensus regarding the papers to be included in the review. We neither performed a risk of bias assessment for individual studies nor computed effect estimates, as this was meant to be a narrative review.
Selected studies were categorized under three broad themes: studies that looked at the biological basis of the association between vitamin D and depression, studies that dealt with quantifying the association between vitamin D and depression, and trials that evaluated the effect of supplementing vitamin D in depression. Accordingly, in this review, we will discuss our search results under these three headings, and finally, we end with a discussion on knowledge gaps in these areas and recommendations to enrich and enhance future research.
RESULTS
Of a total of 148 full-text articles assessed, 116 (78.37 per cent) were published in the last ten years and 82 articles (55.41 per cent) were published in the last five years. These percentages clearly indicate the increasing research focus on the role of vitamin D in depression in the last decade. Totally, 61 articles were included in the present review. Of these, 46 were original articles, 13 were reviews/meta-analysis papers, and two were commentaries.
Vitamin D and depression: Biological underpinnings
The exact biological mechanisms linking vitamin D and depression are not fully understood. However, possible pathways include an imbalance in the calcium homeostasis of intracellular and extracellular compartments and a possible fallout of disequilibrium between glutamate, an excitatory neurotransmitter, and GABA, an inhibitory neurotransmitter. This, in turn, affects cellular signalling. Vitamin D may have a potential role in restoring this calcium and neurotransmitter imbalance by regulating intracellular calcium stores and cellular signalling and impacting the onset of depression favourably. [16] Research has uncovered a possible neurotrophic and immunomodulatory role for vitamin D, leading many researchers to label it as a neurosteroid hormone. [17, 18] Preclinical studies have shown that administration of vitamin D modulates the levels of inflammatory cytokines in the animal models of multiple sclerosis, a neurodegenerative condition with an inflammatory basis. [19] This is important because evidence suggests that depression is also a condition with elevated levels of systemic inflammation. [20, 21] Increased region-specific expression of VDRs has been noted in the prefrontal and cingulate cortices, thalamus, amygdala, and hippocampus, all key brain areas implicated in the pathophysiology of depression. [22] F u r t h e r m o r e , v i t a m i n D m o d u l a t e s t h e hypothalamic-pituitary-adrenal axis, which regulates the production of the monoamine neurotransmitters epinephrine, norepinephrine, and dopamine in the adrenal cortex and also protects against the depletion of dopamine and serotonin. [23, 24] Figure 1 summarizes the possible biological links between depression and vitamin D.
The possibility of reverse causality too has been pointed out by prior investigators. [25, 26] Certain factors related to depression can further increase the risk of vitamin D deficiency in an individual suffering from depression. Depressed individuals may avoid outdoor activity for prolonged periods of time (reducing sunlight exposure); poor appetite may lead to nutritional (and vitamin D) deficiency; metabolic derangements and increased demand for vitamin D (for restoring the calcium homeostasis) might further increase the risk of vitamin D deficiency in depression.
Evidence for the association between vitamin D and depression
Several cross-sectional studies, [27] [28] [29] [30] [31] few cohort studies, [32] [33] [34] and one case-control study [35] have examined the association. All the studies found that depressed subjects had lower levels of vitamin D compared to controls, and those with the lowest vitamin D levels had the greatest risk of depression (odds ratios 1.31, 95 per cent confidence interval [CI] 1.00-1.71). These values, though statistically significant, do not establish clinical relevance beyond doubt. [ 2 9 , 3 0 , 3 3 , 3 6 ] a n d community-based [27, 37] trials show a link between low vitamin D levels and presence and severity of depressive symptoms, it is important to examine if these associations hold good after controlling for relevant demographic, lifestyle, and geographical factors. Encouragingly, community-based trials that controlled for age, gender, smoking, and body mass index have also found an inverse correlation between serum levels of 25(OH)D and levels of depression. [27, 28] These findings are partly tempered by the conclusions from two negative studies among the elderly; one a large Chinese epidemiologic study (n = 3,262) of men and women aged 50-70 years [38] that did not show any association between vitamin D and depression; and the other, a cohort study from Hong Kong (n = 939, all aged more than 65 years), [32] where no relationship was observed between baseline vitamin D level and depression status at four-year follow-up. Notably, both these studies showed that the odds ratios turned insignificant after adjusting for several key confounders.
W h i l e b o t h h o s p i t a l -b a s e d
Evidence for Vitamin D supplementation in depression Vitamin D supplementation for depression in adults
Vitamin D metabolites are capable of crossing the blood-brain barrier, [39] and as mentioned before, VDRs are widespread in key brain areas implicated in depression, including the hippocampus. [17] Hence, it could be speculated that vitamin D supplementation may confer additional therapeutic benefits in depression.
Building on this premise, a number of trials with different methodologies have evaluated the efficacy of vitamin D supplementation in depression in the last decade. However, the findings have been somewhat inconsistent. [40] [41] [42] Partly, the reason may lie in the heterogeneity of trials with respect to sample size, study setting and design, the age range of participants, vitamin D dosing protocols, duration of the intervention, and the outcome measures used.
As studies using heterogeneous designs may be difficult to compare, it becomes important to examine results from randomized controlled trials (RCTs). Four RCTs [43] [44] [45] [46] have evaluated the efficacy of supplemental vitamin D in patients with clinical depression. While three of them evaluated the efficacy of supplemental vitamin D, the fourth one studied the efficacy of vitamin D as an adjunct to standard anti-depressant therapy. All four trials demonstrated benefits for vitamin D, with effect sizes varying from moderate to large. On a discordant note, two recent RCTs [47, 48] found no evidence of any beneficial effect of vitamin D3 supplementation on depressive symptoms or mood-related outcomes. Interestingly, both these negative studies were done on healthy population and not clinically depressed subjects.
Clinical improvement in depressive symptoms with vitamin D supplementation appears to vary depending on several methodological considerations. Spedding [49] noted that therapeutic benefits of vitamin D were more pronounced in studies with fewer 'biological' flaws (such as suboptimal dosing of vitamin D), and worsening in depressive symptoms with vitamin D supplementation was noted in studies with methodological flaws. These perspectives are supported by findings that higher dosages of vitamin D had a greater impact on mental health and wellbeing. [40, 50, 51] Vitamin D supplementation in depression during pregnancy or peripartum period Researchers have found a relationship between low serum vitamin D concentration during pregnancy and elevated postpartum [52, 53] as well as antepartum depression. [54] On a conflicting note, a large nested case-control study (605 women with postpartum depression [PPD] and 875 controls) found a greater probability of postnatal depression with an increase in 25-hydroxyvitamin D concentration. [55] An Iranian RCT on pregnant women found that consuming 2,000 IU vitamin D3 daily during late pregnancy was effective in mitigating perinatal depressive symptoms. [56] In a cross-sectional study from Japan, higher dietary vitamin D intake was independently associated with a lower prevalence of depressive symptoms during pregnancy. [57] One association study showed a significant inverse association between vitamin D levels and risk of antepartum (at 21 weeks, adjusted odds ratios [AOR] 0.54, 95 per cent CI 0.29-0.99) and PPD (at three days, AOR 2.72, 95 per cent CI 1. 42-5.22 ). [58] Similarly, levels of vitamin D in early pregnancy were found to be a marker for elevated depression scores both in early and late pregnancy. [59] These results, though not conclusive, suggest a relationship between serum vitamin D levels and antepartum and PPD.
Vitamin D supplementation in depression in childhood and adolescence
Results from a review of 25 observational and eight longitudinal studies concluded a role for vitamin D in the pathogenesis of several child and adolescent psychiatric conditions, including attention deficit hyperactivity disorder and autism spectrum disorders (ASD). [60] A case series of 54 adolescents with depression found a positive association between vitamin D levels and wellbeing and a greater improvement in depression with vitamin D supplementation. [61] Only one completed RCT is available in this population. This six-month study, done on children with ASD aged 2-12 years, did not find significant benefits for daily oral supplementation of 2,000 IU of vitamin D on autism scores. [62] An RCT aimed at assessing the efficacy of vitamin D supplementation in children and adolescents with depressive disorder is currently underway. [63] The salient features of supplementation trials described in this section are shown in Table 1 . Overall, the available literature supports a relationship between vitamin D and depression in adults as well as children and adolescents. But, on a closer examination, there are several gaps in the evidence, which we outline below.
Gaps in understanding of the relationship between vitamin D and depression Gaps in understanding of the association between vitamin D and depression
Much of the evidence linking vitamin D with depression in adults comes from cross-sectional studies. [64] Cohort or case-control studies are few and RCTs, considered superior for establishing causality, are even fewer. There was no effect of hormone therapy, calcitriol or hormone therapy with calcitriol on depression
In post-menopausal women, there was no effect of hormone therapy and calcitriol either individually or in combination with depression.
Khoraminiya et al., 2013
Iran [43] Randomized controlled trial 42 outpatients aged 18-65 years with a diagnosis of MDD without psychotic features Daily oral 1,500 IU of vitamin D3 plus 20 mg fluoxetine or placebo plus 20 mg fluoxetine for 8 weeks Depression severity decreased significantly in the intervention group compared to controls.
Combination therapy was superior to fluoxetine alone in controlling mood symptoms from the fourth week of treatment Mozaffari-Khosravi et al., 2013 Iran [44] Randomized controlled trial 120 subjects aged 20-60 years with depressive symptoms and vitamin D deficiency Two single intramuscular injections equivalent to 300,000 IU (G300) and 150,000 IU (G150) of vitamin D were compared with a no treatment group (NTG) for 3 months As the bulk of the literature is from observational studies, several questions remain. Chief among them is the issue of small and unrepresentative samples, varying measures of depression (self-report vs. clinician-rated), and the potential problem of reverse causality. Given that two of the important negative studies came from China and Hong Kong, the issue of latitude moderating the association between vitamin D and depression needs further examination.
Significant improvement on Beck depression inventory scores was noted between G300 and NTG, but not between G150 and NTG groups
Owing to several sources of bias in existing studies and the danger of publication bias impacting the literature on vitamin D and depression, the possibility of a meta-analysis answering this question with finality remains bleak. More RCTs are therefore needed to examine the efficacy of supplemental vitamin D on prevention and treatment of depression.
Knowledge gaps in biological underpinnings between vitamin D and depression
Our understanding of the effect of vitamin D on neuronal brain function and behaviour is largely based on animal studies, and there are practically very few human studies. Studies examining the behavioural impact of VDR knock-out in mice have reported an increase in behaviours suggestive of heightened anxiety and psychosis, but not depression (such as greater immobility in tail suspension test). [65, 66] Indeed, research attention on the effect of vitamin D on brain function has been more substantive in schizophrenia than depression.
The impact of vitamin D on monoamines involved in the pathobiology of depression is not well understood either. Vitamin D may upregulate genes involved in the synthesis of tyrosine hydroxylase, an enzyme involved in the synthesis of catecholamines. [18] A protective role for vitamin D in reducing the negative effects of dopaminergic toxins, possibly by increasing glial cell-line derived neurotrophic factor, has been proposed. [67, 68] This may reciprocally affect serotonin transmission in the brain, given the links between dopaminergic and serotonergic systems. Preclinical models also point to a cross-talk between vitamin D and glucocorticoid receptors, and this may hold significance given the dysregulated hypothalamo-pituitary axis in depression. [69] Evidently, more human studies and animal models are required to further our understanding of biological links between vitamin D and depression. This will not only advance our understanding of the various pharmacological therapies but also, potentially, open up new therapeutic targets in depression.
Gaps in understanding the effect of vitamin D supplementation in depression
As summarized earlier, several trials that sought to evaluate the effect of supplemental vitamin D on depression have been published in the last five years. Two subtly different meta-analyses have attempted to summarize the existing data in this regard-one by Gowda et al. [70] that synthesized trials where the outcome of interest was subsyndromal depressive symptoms and the other by Vellekkatt and Menon [71] that only included trials on syndromal or clinical depression.
The results were illuminating. The pooled effect size (standardized mean difference) in the first meta-analysis was 0.28 (95 per cent CI = -0.14 to 0.69) while in the second one, it was 0.58 (95 per cent CI = 0.45 to 0.72). This clearly indicates that adjunctive vitamin D may be more beneficial for subjects with clinical depression than subsyndromal depressive symptoms.
Interestingly, in the Gowda et al. paper, effects remained non-significant in subgroups stratified on serum 25(OH)D levels (cut-off of 50 nmol/l), vitamin D dosing used (cut-off of 4,000 IU/day), and whether vitamin D was used together with other supplements or anti-depressants, implying that these parameters may not be significant moderators in the relationship. Of note, there were limited trials in the Vellekkatt and Menon paper, with one trial contributing disproportionate weight in the meta-analysis. Several sources of bias, such as lack of allocation concealment and blinding, were also noted by the authors. As such, the garbage in, garbage out phenomenon cannot be ruled out.
From the above, it is clear that there are several unknowns in the literature. First, there is a need for larger and more rigorous trials to answer the question of whether the beneficial effects of vitamin D are different in subjects with subsyndromal depression versus syndromal major depression. Second, the biological plausibility that the beneficial effects of vitamin D may be higher in clinically depressed subjects with concurrent vitamin D deficiency emphatically merits further investigation.
And last, there is very little evidence among special populations like pregnant women or postpartum mothers. The available evidence is mostly cross-sectional, and we were able to find only one interventional study [56] in this group. Nevertheless, the positive results of this trial and another related trial that linked prenatal supplementation of vitamin D to a decrease in risk of schizophrenia in the offspring's life [72] are encouraging. Thus, whether supplemental vitamin D may exert benefits on primary prevention of depression is a question that needs to be systematically examined. Further, the directionality of the association between vitamin D and PPD is inconsistent because both high and low vitamin D levels have been shown to be associated with a risk of PPD. [73] Other important gaps in evidence include a lack of clarity on whether a change in vitamin D levels parallels that of depressive symptoms following treatment. This would be expected if, indeed, vitamin D and depression share a cause-effect relationship. Studying the relationship between change in inflammatory marker status and vitamin D levels in major depression will throw more light on the three-way association and aid understanding of the mediating mechanisms involved in the purported benefits of vitamin D in depression.
Recommendations for future research
Based on the above, we propose the following recommendations that may be kept in mind by prospective researchers who intend to study the preventive and therapeutic roles of vitamin D in depression: 1. Use standard doses/duration/frequencies/route of administration of vitamin D: Preliminary evidence shows that oral and parenteral routes are comparable in efficacy, but compliance is likely to be of greater concern in oral supplementation. Parenteral supplementation may be more efficient in this regard, and there are supporting studies showing beneficial effects of a single adjunctive parenteral dose of vitamin D in depression [44] 2. Address key methodological issues: Based upon the findings from an interesting meta-analysis [49] , which found a significantly higher effect size for vitamin D in depression when combining trials without methodological flaws, a few important recommendations can be made. First, researchers must avoid ineffective interventions, which in this context means those that do not change the vitamin D status of the patient. Second, researchers must strive to measure vitamin D levels of depressed subjects at baseline and target subjects with vitamin D deficiency (defined as levels less than 20 ng/ml) rather than vitamin D insufficiency (defined as 21-29 ng/ml) when the aim is to evaluate the therapeutic effects of supplemental vitamin D in depression. [74] Ethno-specific desirable reference ranges for vitamin D need to be computed, keeping in mind the effect of confounders such as age, sex, and ultraviolet B (UVB) radiation. [75] Whenever possible, the goal of supplementation must be to change the vitamin D status of the trial participant. As substantiated earlier, it also appears to be a sound idea to enrich vitamin D trials with depressed subjects also having concurrent vitamin D deficiency. Based on the available evidence, it appears that, for favourable benefits in depression, a supplemental dose of ≥800 IU daily for 4-6 weeks or a single parenteral dose of 3,00,000 IU of vitamin D should be given along with initiation of antidepressant treatment. The question of how long to continue supplementation is less clear, but it is probably beneficial to give until there is a change in vitamin D status of the patient (from deficient or insufficient to normal) 3. Use uniform assay procedures and outcome measures: This is necessary to facilitate inferences. Researchers must develop standard protocols for vitamin D assay and supplementation in clinical practice. The recommended assay to measure different types of vitamin D is the chromatographic procedure of liquid chromatography-tandem mass spectrometry (LC-MS/MS). [76] Uniform instruments must be used to assess depression outcomes of interest. Adhering to these steps would, undoubtedly, enhance cross-cultural comparability of findings 4. Identify depression subgroups that would benefit maximally from supplemental vitamin D: Just as there appears to exist an inflammatory biotype of depression, [77] it also seems plausible that there is a subset of patients with depression who may benefit maximally from vitamin D supplementation. The challenge for us is to find out that subpopulation, and enriched trials certainly appear to be a step forward to achieve this. From the available literature, it appears that patients who are obese, elderly, adolescent, or homebound and those with chronic illness may be more likely to benefit from vitamin D-based interventions, and this merits further study 5. Estimate concurrent changes in vitamin D, inflammatory markers, and depression: Researchers should try to evaluate whether changes in vitamin D levels and systemic inflammatory markers parallel that of depression scores. This will provide further evidence to support the links between vitamin D and depression and also give valuable insights into the biological mechanisms behind this association 6. Investigate the benefits of suprathreshold dosing of vitamin D: Thus far, the available trials have only looked at using supplementation to correct preexisting vitamin D deficiency. It may be worthwhile to check if additional supplementation helps with residual symptom management in depression and prevention of further episodes 7. Adequate adjustment for confounding factors: This is important, to avoid the danger of spurious associations. There are many important confounders that researchers should be aware of, and these include both demographic and lifestyle factors. Additionally, in special populations such as postpartum mothers, controlling for variables including, but not limited to, social support, the gender of the baby, and the educational status of the mother assumes significance. Figure 2 depicts the key confounding factors in the relationship between vitamin D and depression.
CONCLUSION
The evidence clearly supports a relationship between vitamin D and depression, though the directionality of the association can be contested. This is partly because most of the evidence comes from cross-sectional studies. The biological links between the two can be explained on the basis of the homeostatic, immunomodulatory, and neuroprotective roles of vitamin D. Pooled evidence from RCTs suggest superior therapeutic benefits of vitamin D supplementation in clinical, rather than subsyndromal, depression. Many gaps in evidence remain, and this must be addressed through future trials that employ uniform assays, dosing protocols, and outcome measures. Adequate control of confounders and enriching depression trials with subjects also having concurrent vitamin D deficiency appear to be key steps forward in delivering results that would be scientifically sound, valid, and translational.
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